Company / Shareholders' Equity
Ultragenyx Pharmaceutical Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$80.0M
FY2025
5-year range
-$80.0M / $653.8M
FY2021-FY2025
Trend
-131.4%
vs FY2024
Sector context
#197 of 213
Health Care
What the data says
Ultragenyx Pharmaceutical Inc. reports negative total equity of -$80M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$80M in FY2025.
Declined from $275M to -$80M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 213This company -$80.0M Sector average $2.5B
▼
-103.1% below sector average
Key checks
Key Insights
- Ultragenyx Pharmaceutical Inc.'s shareholders' equity has declined for 4 consecutive years.
- In FY2025, shareholders' equity decreased 131.4% year-over-year.
- Ranks #197 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$80.0M | -131.4% |
| FY2024 | $255.0M | -7.3% |
| FY2023 | $275.0M | -21.9% |
| FY2022 | $352.0M | -46.2% |
| FY2021 | $653.8M | +7.4% |
| FY2020 | $608.9M | +58.8% |
| FY2019 | $383.5M | -37.0% |
| FY2018 | $608.9M | +14.7% |
| FY2017 | $531.1M | +187.2% |
| FY2016 | $184.9M | -65.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026